New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT02964013
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This early-phase study tested a new drug called vibostolimab (MK-7684), either alone or combined with pembrolizumab and other chemotherapy drugs, in adults with advanced solid tumors that had no standard treatment options. The main goals were to check safety, find the right dose, and see if the drug shrinks tumors. The study involved 474 participants and is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.